Alternative Dosing Strategies for Immune Checkpoint Inhibitors

Panel Explores Emerging Treatments and Sequencing Strategies for Patients with Advanced NSCLCs Driven by Rare Oncogenes

Evidence Supports Adding Biological, Pathological, and Molecular Assessments to the TNM Lung Cancer Staging System

Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates

Using Comparative Effectiveness Data Based on Non-Randomized Study Designs to Support Regulatory, Reimbursement Decision-Making

In Measuring Outcomes, a Longer-Term View May be Needed

Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients

More Robust Tools Needed to Predict who will Respond to Immune Checkpoint Inhibitors

NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition

Growing Body of Evidence Highlights Potential Applications for Liquid Biopsy in Clinical Practice

When Perfect is the Enemy of Good: Investigators Compare Rigorous Clinical Trial Data to Real-World Experience

HER2 Mutations Present Unique Challenges in NSCLC